ライフサイエンスコーパス: oncolytic adenovirus

1 ficantly enhanced the antitumor effect of an oncolytic adenovirus.

2 osylation states and cancer treatments using oncolytic adenovirus.

3 and has implications for cancer therapy with oncolytic adenoviruses.

4 al strategy to optimize clinical efficacy of oncolytic adenoviruses.

5 ill be required for a complete evaluation of oncolytic adenoviruses.

6 ptibility of primary ovarian cancer cells to oncolytic adenoviruses.

7 ility of tumor cells to systemically applied oncolytic adenoviruses.

8 llent candidates for generating HCC-specific oncolytic adenoviruses.

9 fety trait to be considered in the design of oncolytic adenoviruses.

10 preliminary efficacy (secondary endpoint) of oncolytic adenovirus Ad-TD-nsIL12 in primary (Group A, N

11 ation of dendritic cells (DCs) combined with oncolytic adenovirus (Ad) expressing antitumor cytokines

12 We have constructed a novel oncolytic adenovirus (Ad) vector named VRX-009 that comb

13 Oncolytic adenovirus (Ad) vectors present a promising mo

14 We use a newly designed tumor-targeted oncolytic adenovirus (Ad-TD) to deliver non-secreting (n

15 Oncolytic adenoviruses (Ad) are a potential treatment op

16 In this study, we constructed a novel oncolytic adenovirus, Ad5/3-hTERT-E1A-hCD40L, which feat

17 ribution of a potent breast cancer-selective oncolytic adenovirus, AdEHE2F-Luc, to tumour regions tha

18 Although oncolytic adenoviruses (Ads) are an attractive option fo

19 implications for clinical use of E3B-deleted oncolytic adenovirus and other E3B-deleted adenovirus ve

20 stify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the trea

21 y suggest a possible interaction between the oncolytic adenovirus and/or double-suicide gene therapie

22 ave important implications for the design of oncolytic adenoviruses and may explain the rapid clearan

23 roducts, are applicable to the production of oncolytic adenoviruses and other cell-based products, an

24 ach, allows for immediate screening of novel oncolytic adenoviruses and selection of optimal viral ge

25 mechanistic rationale for the combination of oncolytic adenoviruses and temozolomide, and should prop

26 Replication-selective oncolytic adenoviruses are being developed for the treat

27 Oncolytic adenoviruses are promising therapies for the t

28 The use of oncolytic adenoviruses as a cancer therapeutic is depend

29 ent a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments.

30 indicate that this improved stroma-targeted oncolytic adenovirus can override the resistance of mela

31 our PeptiCRAd technology that consists of an oncolytic adenovirus coated with MHC-I-restricted tumor-

32 c administration of a replication-competent, oncolytic adenovirus containing a cytosine deaminase (CD

33 viously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can targe

34 A novel oncolytic adenovirus, CRAd-Survivin-pk7, showed signific

35 nd activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells (NSC

36 y DNA repair genes, we hypothesized that the oncolytic adenovirus Delta-24-RGD could be successfully

37 studies, we show that BM-hMSCs carrying the oncolytic adenovirus Delta-24-RGD prolonged the survival

38 ata from a previous clinical trial using the oncolytic adenovirus Delta-24-RGD showed that generation

39 To test the hypothesis, we first constructed oncolytic adenovirus Delta-24-RGDOX expressing the immun

40 , we evaluated the mechanisms of LOAd713, an oncolytic adenovirus designed to block IL-6R signaling a

41 etostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate i

42 hours following in vitro infection with the oncolytic adenovirus dl922-947.

43 /DeltaE3), a previously described E3-deleted oncolytic adenovirus encoding GM-CSF.

44 hTNFalpha-IRES-hIL-2) is a serotype chimeric oncolytic adenovirus encoding tumor necrosis factor alph

45 med tumor cells may provide insight into how oncolytic adenoviruses exploit metabolic transformation

46 ovirus vectors and which can be killed by an oncolytic adenovirus expressing adenovirus E1A and tumor

47 rial to study the safety of Ad-TD-nsIL12, an oncolytic adenovirus expressing non-secreting interleuki

48 Data are presented showing that oncolytic adenoviruses expressing the relaxin gene and c

49 er, the reintroduction of the E3 region into oncolytic adenoviruses has been found to positively infl

50 Oncolytic adenoviruses have been considered for use as a

51 Human oncolytic adenoviruses have been used in clinical trials

52 We previously developed an oncolytic adenovirus (HYPR-Ad) for the specific killing

53 The oncolytic adenovirus ICOVIR-15K was engineered to expres

54 n, which greatly enhances the activity of an oncolytic adenovirus in the presence of low-dose radioth

55 del that more accurately reflects the use of oncolytic adenoviruses in cancer patients.

56 have demonstrated good therapeutic index for oncolytic adenoviruses in patients with solid tumours wh

57 d therapeutic index of replication-selective oncolytic adenoviruses in patients, we believe that enco

58 The CB1 oncolytic adenovirus induces a potent antiglioma effect

59 Furthermore, i.t. oncolytic adenovirus injection resulted in suppression o

60 Oncolytic adenovirus injection showed efficacy in three

61 Oncolytic adenovirus is an attractive platform for immun

62 allows the effective testing of mouse armed oncolytic adenovirus (MAV) vectors in immunocompetent sy

63 The therapeutic value of similar oncolytic adenoviruses may be improved by abrogating E4o

64 egulation of autophagy in cells treated with oncolytic adenoviruses may provide new avenues to improv

65 CAdVEC (NCT03740256), representing a dose of oncolytic adenovirus more than 100-fold lower than used

66 accine platform that combines an immunogenic oncolytic adenovirus (OAd) coated with tumor antigen pep

67 Oncolytic adenovirus (oAd)-mediated gene therapy is a pr

68 used ECM-degrading and Wnt signal-disrupting oncolytic adenovirus (oAd/DCN/LRP) to achieve a desirabl

69 models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad

70 at intratumor vaccination with a recombinant oncolytic adenovirus overexpressing the HSP70 protein ca

71 E-MCs) to achieve antigen-guided delivery of oncolytic adenoviruses (OVs) and local immune activation

72 Oncolytic adenoviruses produce clinical benefits, partic

73 Replication-selective oncolytic adenoviruses represent a novel cancer treatmen

74 Replication-selective oncolytic adenoviruses represent a promising new platfor

75 Oncolytic adenoviruses represent a promising therapeutic

76 Oncolytic adenoviruses represent an innovative approach

77 Intratumoral administration of 01/PEME, an oncolytic adenovirus, required approximately 1000-fold l

78 Oncolytic adenoviruses, such as Delta-24-RGD (Delta24RGD

79 Oncolytic adenoviruses, such as Delta-24-RGD, are promis

80 xt generation of transcriptionally regulated oncolytic adenoviruses take advantage of the ability of

81 ents a barrier to infection by commonly used oncolytic adenoviruses targeted to coxsackie-adenovirus

82 oof-of-principle evidence that an attenuated oncolytic adenovirus that selectively lyses cells under

83 enter, dose-escalation study of DNX-2401, an oncolytic adenovirus that selectively replicates in tumo

84 has been substituted for the E3-gp19 gene in oncolytic adenoviruses that otherwise retained the E3 re

85 more effectively activated and redirected by oncolytic adenoviruses that were armed with bispecific T

86 linical trials and the established safety of oncolytic adenoviruses, the in vivo function of these ag

87 Our study has implications for oncolytic adenovirus therapy.IMPORTANCE Previously, it h

88 r (hTERT), with the beneficial effects of an oncolytic adenovirus to deliver the gene for the prodrug

89 Here we use an oncolytic adenovirus to deliver the prodrug-activating e

90 Clinical trials have shown oncolytic adenoviruses to be tumor selective with minima

91 we showed for the first time the ability of oncolytic adenoviruses to enhance E2F transcriptional ac

92 nents within tumors, which helps recombinant oncolytic adenoviruses to spread effectively throughout

93 Targeting of oncolytic adenoviruses to tumors can potentially increas

94 The vast majority of oncolytic adenoviruses used in clinical trials to date h

95 Our results support the use of oncolytic adenoviruses using tumor-selective promoter(s)

96 omolog model for the testing of murine armed oncolytic adenovirus vectors in immunocompetent animals.

97 may become a valuable tool for the field of oncolytic adenovirus vectors in which vector safety and

98 sm of replication-competent viruses, such as oncolytic adenoviruses, vesicular stomatitis virus, and

99 The intra-arterial infusion of oncolytic adenoviruses warrants additional study.

100 intratumoral infection, tumor eradication by oncolytic adenovirus will probably require potent suppre

101 dl922-947, an oncolytic adenovirus with a 24-bp deletion in E1A CR2, r

102 ctivity-augmented, conditionally replicative oncolytic adenovirus with significant antiglioma effects

103 LOAd703, an oncolytic adenovirus with transgenes encoding TMZ-CD40L

104 Overall, our results show how arming oncolytic adenoviruses with BiTE can overcome key limita